Moteur de recherche d’entreprises européennes

18 Financements de l’UE (total 12,8 M €) : Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe … BdlAnnée 2022 Programme de recherche et d'innovation de l'UE « Horizon »

Texte

The Brønnøysund Register Centre 993467049

04/09/2022 Financement de l’UE (10,3 M €) : Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness
29/12/2022 Financement de l’UE (10,6 M €) : Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
01/07/2022 Financement de l’UE (12,4 M €) : eBRAIN-Health - Actionable Multilevel Health Data
05/08/2022 Financement de l’UE (12 M €) : A clinical research network to improve the management of Monkeypox virus disease
26/08/2022 Financement de l’UE (1 457 000 €) : Diabetes, obesity and the Kidney
16/09/2022 Financement de l’UE (1 500 000 €) : Final act of the autophagy symphony: Whole-organism orchestration of autophagy termination
01/02/2022 Financement de l’UE (21 M €) : Integrated Services for Infectious Disease Outbreak Research
12/08/2022 Financement de l’UE (284 180 €) : Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography.
04/09/2022 Financement de l’UE (2 734 402 €) : Combination therapy for the treatment of metastatic melanoma using magnetic nanoparticles
30/09/2022 Financement de l’UE (3 337 725 €) : Supervised morphogenesis in gastruloids
02/08/2022 Financement de l’UE (4 674 996 €) : OPTIMISING COLORECTAL CANCER PREVENTION TROUGH PERSONALISED TREATMENT WITH ARTIFICIAL INTELLIGENCE
01/09/2022 Financement de l’UE (4 773 470 €) : Developing and implementing innovative Patient-Centred Care Pathways for cancer patients
03/08/2022 Financement de l’UE (4 883 229 €) : Implementing a patient-centred and evidence-based intervention to reduce BEnzodiazepine and sedative-hypnotic use to improve patient SAFEty and quality of care
01/07/2022 Financement de l’UE (6 393 734 €) : Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology
01/08/2022 Financement de l’UE (7 984 441 €) : Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training.
28/07/2022 Financement de l’UE (8 190 468 €) : Intelligent Ecosystem to improve the governance, the sharing and the re-use of health Data for Rare Cancers
01/06/2022 Financement de l’UE (9 045 288 €) : Reducing the impact of major environmental challenges on mental health
29/11/2022 Financement de l’UE (9 197 628 €) : Maximising Impact of Prescription Drugs in Rheumatoid Arthritis

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Oslo Universitetssykehus HF, Oslo, Norvège.